This is a preview of subscription content, log in via an institution to check access.
References
Klareskog L, van der Heijde D, de Jager JP, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675–681.
Genentech, Xoma’s Raptiva fails to meet endpoint in phase II psoriatic arthritis trial [press release]. Fax Watch: March 22, 2004.
Kraan MC, van Kuijk AW, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776–2784.
Bluestone JA, St Clair EW, Turka LA: CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006, 24:233–238.
Abrams JR, Lebwohl MG, Guzzo CA, et al.: CTLA4Igmediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243–1252.
Rights and permissions
About this article
Cite this article
Ritchlin, C.T. The eficacy and safety of alefacept in psoriatic arthritis. Curr Rheumatol Rep 8, 330–331 (2006). https://doi.org/10.1007/s11926-006-0060-0
Issue Date:
DOI: https://doi.org/10.1007/s11926-006-0060-0